share_log

4: Statement of changes in beneficial ownership of securities-Officer Claiborne Cary J

4: Statement of changes in beneficial ownership of securities-Officer Claiborne Cary J

4:持股变动声明-高管 Claiborne Cary J
美股SEC公告 ·  2024/12/06 06:49

Moomoo AI 已提取核心信息

Claiborne Cary J, CEO of Adial Pharmaceuticals, reported no transactions involving non-derivative securities as of 12/05/2024. The announcement indicates that there were no changes in his stock holdings during this period.This report is significant for investors monitoring insider activities, as it confirms the absence of stock sales or purchases by the CEO. Such information can be crucial for assessing insider confidence in the company's future performance.Investors should note that the lack of transactions does not imply any specific outlook on the company's stock performance. It merely reflects the current status of the CEO's holdings as of the reported date.
Claiborne Cary J, CEO of Adial Pharmaceuticals, reported no transactions involving non-derivative securities as of 12/05/2024. The announcement indicates that there were no changes in his stock holdings during this period.This report is significant for investors monitoring insider activities, as it confirms the absence of stock sales or purchases by the CEO. Such information can be crucial for assessing insider confidence in the company's future performance.Investors should note that the lack of transactions does not imply any specific outlook on the company's stock performance. It merely reflects the current status of the CEO's holdings as of the reported date.
截至2024年5月12日,Adial Pharmicals首席执行官克莱伯恩·卡里·J没有报告任何涉及非衍生证券的交易。该公告表明,在此期间,他的股票持有量没有变化。该报告对监督内幕活动的投资者具有重要意义,因为它证实了首席执行官没有出售或购买股票。这些信息对于评估内部人士对公司未来业绩的信心可能至关重要。投资者应注意,缺乏交易并不意味着对公司股票表现有任何具体展望。它仅反映了首席执行官截至报告日的持股现状。
截至2024年5月12日,Adial Pharmicals首席执行官克莱伯恩·卡里·J没有报告任何涉及非衍生证券的交易。该公告表明,在此期间,他的股票持有量没有变化。该报告对监督内幕活动的投资者具有重要意义,因为它证实了首席执行官没有出售或购买股票。这些信息对于评估内部人士对公司未来业绩的信心可能至关重要。投资者应注意,缺乏交易并不意味着对公司股票表现有任何具体展望。它仅反映了首席执行官截至报告日的持股现状。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息